Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Hepatitis Delta virus is the smallest known human virus, exploiting the HBV surface proteins (HBsAg) for the release of its progeny and de novo entry into hepatocytes. Ever growing evidence have highlighted the existence of multiple mechanisms underlying HDV persistence including integrated HBV-DNA as a source of HBsAg production and the capability of the HDV genome to propagate through cell proliferation, thus supporting a potential HDV persistence even in the absence of HBV. Chronic HDV-infection causes the most severe form of viral hepatitis, leading to the development of cirrhosis in 15% of cases within 1-2 years and in 50%-60% of cases within 5-10 years. The rates of hepatocellular carcinoma and hepatic decompensation are also 2-3-fold higher than for HBV mono-infection. There is the evidence that persistent viral replication plays a key role in triggering liver injury, suggesting the existence of direct viral cytopathic properties that can modulate, synergistically with immune-responses, the progression towards end-stage liver diseases. All these aspects can be further exacerbated by the extraordinary degree of viral genetic variability that can promote HDV evasion from immune responses and has enabled viral differentiation into genotypes and subgenotypes with potential different pathobiological properties. In this light, this review aims at providing comprehensive insights of mechanisms (with a focus on virological factors) underlying HDV persistence and pathogenesis, critical in shaping the clinical outcome of the infection. Dissecting these mechanisms is pivotal to optimize therapeutic strategies aimed at fully counteracting this fascinating and fearsome virus.

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13755DOI Listing

Publication Analysis

Top Keywords

hdv persistence
12
mechanisms underlying
8
hepatitis delta
8
delta virus
8
persistence pathogenesis
8
underlying hdv
8
hdv
5
viral
5
novel concepts
4
mechanisms
4

Similar Publications

Background: Hepatitis D virus (HDV) infection is the most severe form of human viral hepatitis. A poor virus-specific CD8T cell response may result in persistent HDV infection. We investigated anti-viral effect and mechanisms of ubiquitinated small hepatitis D antigen (Ub-S-HDAg) in HBV/HDV superinfected liver organoids.

View Article and Find Full Text PDF

Chronic hepatitis delta (CHD) represents the most severe form of viral hepatitis due to rapid disease progression towards liver cancer, leading to high morbidity and mortality. Hepatitis delta virus (HDV) can only infect individuals who are infected with hepatitis B. So far, there is no cure or vaccine for HDV.

View Article and Find Full Text PDF

Hepatitis B virus (HBV) infection affects >290 million people worldwide, including ∼250,000 Canadians, and it stands as a leading cause of end-stage liver disease and liver cancer. The World Health Assembly has set goals for HBV elimination by 2030, aiming for a >90% reduction in incidence and a 65% reduction in deaths compared to 2015. However, as of 2023, no countries were on track to achieve these targets.

View Article and Find Full Text PDF

[New therapeutic strategies against B and D hepatitis].

Virologie (Montrouge)

June 2025

Laboratoire de virologie, CHU de Rennes, 2 rue Henri le Guilloux, 35033 Rennes cedex 9, France, Université de Rennes, Inserm, EHESP, Institut de recherche en santé, environnement et travail (Irset), UMR_S 1085, 35000 Rennes.

Current treatments against the hepatitis B virus (HBV) efficiently inhibit viral replication but rarely lead to functional cure, defined as the loss of HBsAg. Persisting transcription from intranuclear forms of viral DNA, independently from viral replication, limits the possibility of a robust clearing response of the host against the virus. The new therapeutic approaches target either the transcription, with specific oligonucleotides, the capsid assembly or the release of complete viral particles from infected hepatocytes.

View Article and Find Full Text PDF

Hepatitis D Virus Infection: Pathophysiology, Epidemiology and Treatment. Report From the Third Delta Cure Meeting 2024.

Liver Int

July 2025

Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Chronic infection with hepatitis delta virus (HDV) leads to rapid progression of liver disease, cirrhosis and complications such as end-stage liver disease and hepatocellular carcinoma. In recent years, understanding of the HDV life cycle has increased significantly; however, much remains unknown about the pathogenesis, host-virus interactions and the role of the immune system in HDV persistence and control. Challenges remain in the diagnosis of HDV, not only because of the lack of standardised assays, but also because of limited access and availability in resource-limited countries.

View Article and Find Full Text PDF